Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study
PLOS ONE · 06.09.2023 · 18 (9) · e0290549
DOI: 10.1371/journal.pone.0290549 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, online erschienen am 06.09.2023. Verfasst von Margaret-Ann Tait und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Chronic Pain, Medical Marijuana. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Little Green Pharma Ltd.
Abstract (Originalsprache)
Aims
Patients with chronic health conditions not responding to conventional treatment can access medicinal cannabis (MC) prescriptions from clinicians in Australia. We aimed to assess overall health-related quality of life (HRQL), pain, fatigue, sleep, anxiety, and depression in a large real-world sample of patients accessing prescribed medicinal cannabis. We hypothesized that all patient-reported outcomes (PROs) would improve from baseline to 3-months.
Methods
The QUEST Initiative is a large prospective multicenter study of patients with any chronic health condition newly prescribed medicinal cannabis between November 2020 and December 2021. Eligible patients were identified by 120 clinicians at medical centers across six Australian states. Consenting participants completed the EuroQol Group EQ-5D-5L health status questionnaire; European Organization for Research & Treatment of Cancer Quality of Life questionnaire (QLQ-C30); Patient-Reported Outcomes Measurement Information System (PROMIS) Short Forms in Fatigue and Sleep Disturbance, and the Depression Anxiety Stress Scale (DASS-21) before starting therapy, at 2-weeks titration, then monthly for 3-months.
Results
Of the 2762 consenting participants, 2327 completed baseline and at least one follow-up questionnaire. Ages ranged between 18–97 years (mean 51y; SD = 15.4), 62.8% were female. The most commonly treated conditions were chronic pain (n = 1598/2327; 68.7%), insomnia (n = 534/2327; 22.9%), generalized anxiety (n = 508/2327; 21.5%), and mixed anxiety and depression (n = 259/2327; 11%). Across the whole cohort both EQ-5D-5L utility scores and QLQ-C30 summary scores showed clinically meaningful improvement in HRQL from baseline to mean follow-up with d = 0.54 (95%CI:0.47 to 0.59) and d = 0.64 (95%CI:0.58 to 0.70) respectively; and clinically meaningful improvement in fatigue (d = 0.54; 95%CI:0.48 to 0.59). There was clinically meaningful reduction of pain for those with chronic pain (d = 0.65; 95%CI:0.57 to 0.72); significant improvements for those with moderate to extremely severe anxiety ( X 2 = 383; df = 4; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, Sydney Nursing School, The University of Sydney, Sydney, New South Wales, Australia.
- School of Population Health, Curtin University, Perth, Australia.
- Little Green Pharma, West Perth, Western Australia, Australia.
- College of Science, Health, Engineering and Education, Murdoch University, Perth, Western Australia, Australia.
- School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
ORCID-Profile: Margaret-Ann Tait
Förderung
- Little Green Pharma Ltd
Zitieren
APA
Tait, M. A., Costa, D. S. J., Campbell, R., Norman, R., Warne, L. N., Schug, S., & Rutherford, C. (2023). Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study. PLOS ONE, 18(9), e0290549. https://doi.org/10.1371/journal.pone.0290549
Vancouver
Tait MA, Costa DSJ, Campbell R, Norman R, Warne LN, Schug S, et al. Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study. PLOS ONE. 2023;18(9):e0290549. doi:10.1371/journal.pone.0290549
BibTeX
@article{Tait2023,
author = {Tait, Margaret-Ann and Costa, Daniel S J and Campbell, Rachel and Norman, Richard and Warne, Leon N and Schug, Stephan and Rutherford, Claudia},
title = {Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {9},
pages = {e0290549},
doi = {10.1371/journal.pone.0290549}
}
EUVIMED